Search

Your search keyword '"Zhanglin Lin"' showing total 313 results

Search Constraints

Start Over You searched for: Author "Zhanglin Lin" Remove constraint Author: "Zhanglin Lin"
313 results on '"Zhanglin Lin"'

Search Results

1. Engineering quorum sensing-based genetic circuits enhances growth and productivity robustness of industrial E. coli at low pH

2. Achieving robust synthetic tolerance in industrial E. coli through negative auto-regulation of a DsrA-Hfq module

3. A novel protein purification scheme based on salt inducible self-assembling peptides

4. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

5. CRISPR RNA-Guided Transposases Facilitate Dispensable Gene Study in Phage

6. Improved compound–protein interaction site and binding affinity prediction using self-supervised protein embeddings

7. Synthetic acid stress-tolerance modules improve growth robustness and lysine productivity of industrial Escherichia coli in fermentation at low pH

8. Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer

9. A modular pathway engineering strategy for the high-level production of β-ionone in Yarrowia lipolytica

10. Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine

11. Engineered global regulator H-NS improves the acid tolerance of E. coli

12. Characterization of Two Pseudomonas aeruginosa Viruses vB_PaeM_SCUT-S1 and vB_PaeM_SCUT-S2

14. Heat-inducible autolytic vector for high-throughput screening

15. Significant rewiring of the transcriptome and proteome of an Escherichia coli strain harboring a tailored exogenous global regulator IrrE.

16. Laboratory-evolved mutants of an exogenous global regulator, IrrE from Deinococcus radiodurans, enhance stress tolerances of Escherichia coli.

17. Screening of random peptide library of hemagglutinin from pandemic 2009 A(H1N1) influenza virus reveals unexpected antigenically important regions.

20. Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

23. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study

26. Mitigating Host Burden of Genetic Circuits by Engineering Autonegatively Regulated Parts and Improving Functional Prediction

27. Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States

29. Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer

30. Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer

33. Abstract P1-18-37: Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 and 6i for HR+, HER2- MBC in the real world

35. Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer

36. Defining treatment regimens and lines of therapy using real-world data in oncology

40. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

41. Genomic Iterative Replacements of Large Synthetic DNA Fragments in

43. Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States

44. Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

45. Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States

46. Cleavable Self-Aggregating Tags (cSAT) for Therapeutic Peptide Expression and Purification

49. Study of patient characteristics, treatment patterns

Catalog

Books, media, physical & digital resources